Draft:John Simard
| Submission declined on 26 October 2024 by Ca (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Most sources mainly cover the company XBiotech, giving little biographical information about the subject of this draft himself. In addition this article is a simple interview. so iIThis draft also has a promotional tone, especially in the "Research", while omitting concerns raised in the Austin American-Statesman. Ca talk to me! 12:52, 26 October 2024 (UTC)
John Simard | |
|---|---|
| Born | John Simard 1961 (age 62–63) |
| Alma mater | University of Saskatchewan University of Toronto |
| Occupation | Businessperson |
John Simard (born 1961) is a Canadian-born biotechnology entrepreneur and the founder and CEO of XBiotech.[1][2]
Early life and education
[edit]John Simard was born in 1961 in Montreal, Quebec, Canada.[1] He earned a biochemistry degree from the University of Saskatchewan in 1992, then pursued graduate studies in immunology at the University of Toronto's Department of Medical Biophysics.[3][4]
In 1994, Simard left his graduate program to work with Tak W. Mak at the Amgen Research Institute, where he co-authored a textbook on immunology with Mak.[4] He also co-authored a manuscript with Nobel Laureate Rolf Zinkernagel, focusing on the biology of cytotoxic T lymphocytes (CTL).[4]
Career
[edit]Simard began his career in biotechnology by establishing CTL Immunotherapies in 1997, a developer of therapeutic vaccine.[1][5] Later, he also founded AlleCure Corp. in Valencia, California, which developed allergy treatments and immune modulating therapies.[6][5] His first two companies were eventually merged with MannKind Corporation. Simard remained in MannKind as president of its immunology division and a member of the board of directors.[1][7][8]
In 2005, Simard founded XBiotech, which specializes in the research and development of human-derived antibody therapeutics for cancer, inflammatory and infectious diseases.[1][3]
Research
[edit]Simard has pioneered immunotherapies targeting interleukin 1-alpha, including a neutralizing antibody that was sold for a total of $1.35 billion in cash and potential milestone payments.[9][4] He holds over 300 issued and pending patents in areas such as cancer antigen identification, immunotherapies for cancer and infectious diseases, and techniques for identifying and cloning human antibodies.[4]
References
[edit]- ^ a b c d e https://www.bizjournals.com/austin/print-edition/2014/10/17/meet-john-simard-ceo-of-xbiotech.html
- ^ https://www.bizjournals.com/austin/news/2020/06/11/austins-top-paid-ceos.html
- ^ a b "John Simard, Xbiotech USA Inc: Profile and Biography". Bloomberg.com.
- ^ a b c d e "John Simard". XBiotech.
- ^ a b Rockwell, Lilly. "How Austin's XBiotech aims to revolutionize drug discovery". Austin American-Statesman.
- ^ Institute, ERI Economic Research. "John Simard Salary Infomation 2022". ERI Economic Research Institute.
- ^ "BIOTECH---Mann Slates Biotech IPO by Year End". 13 May 2001.
- ^ https://www.bizjournals.com/austin/print-edition/2011/01/28/xbiotech-has-huge-plans.html
- ^ https://www.bizjournals.com/austin/news/2020/02/10/1-35b-deal-offers-vindication-runway-for-austin.html